Origin: Funding, Investors & Team (Sep 2026)
Origin is a clinical-stage biotech company that is privately owned. They are currently working on a medical technology that delivers therapeutic molecules. Their primary focus is on delivering nitric oxide in a targeted manner to treat various conditions such as pain, inflammation, wounds, ulcers, and skin and soft tissue infections. Their aim is to improve and prolong lives through the application of their medical technology in both medicine and agribusiness.
Origin has raised $1.2M across 3 funding rounds on record, the most recent an undisclosed round of $50k announced in Oct 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Origin Company Profile and Key Stats
Latest funding round on record: Oct 2023.
Origin Funding Rounds
Origin raised $500k in a Seed announced in Sep 2022.
9 months later, a Seed of $660k was announced in Jun 2023.
4 months later, an undisclosed round of $50k was announced in Oct 2023.
Origin Founders and Leadership Team
No contact details are on record for this team yet.
Origin Funding Compared to Other Biotechnology Startups
Origin's latest round of $50k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Origin in Biotechnology and Princeton
Companies Similar to Origin
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Origin Funding FAQs
What does Origin do?
Origin is a clinical-stage biotech company that is privately owned. They are currently working on a medical technology that delivers therapeutic molecules. Their primary focus is on delivering nitric oxide in a targeted manner to treat various conditions such as pain, inflammation, wounds, ulcers, and skin and soft tissue infections. Their aim is to improve and prolong lives through the application of their medical technology in both medicine and agribusiness.
How much funding has Origin raised?
Origin has raised $1.2M across 3 rounds on record. The most recent is an undisclosed round of $50k announced in Oct 2023.
When did Origin last raise funding?
Origin's most recent funding round on record is an undisclosed round of $50k, announced in Oct 2023.
Who is the CEO of Origin?
Michael D Preston is listed as CEO at Origin.
Where is Origin headquartered?
Origin is based in Princeton, New Jersey, United States.
How many employees does Origin have?
Origin is in the 1-10 employee band.
How does Origin's funding compare to other Biotechnology startups?
Origin's latest round of $50k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Origin Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Origin is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.